ReproNovo SA | WebDisclosure

Basculer en Français

9472	Companies
185369	Keywords
117719	Articles
99261	Press releases

Home
Companies
ReproNovo SA

BRIEF

published on 09/30/2025 at 07:05, 2 months 4 days ago

ReproNovo Gains Approval for RPN-001 Clinical Trial in China

Clinical Trial China Approval ReproNovo Reproductive Medicine RPN-001
BRIEF

published on 09/30/2025 at 07:05, 2 months 4 days ago

ReproNovo obtient l'approbation pour l'essai clinique RPN-001 en Chine

Essai Clinique ReproNovo RPN-001 Approbation De La Chine Médecine De La Reproduction
PRESS RELEASE

published on 09/30/2025 at 07:00, 2 months 4 days ago

ReproNovo Announces Clinical Trial Approval Notice for RPN-001 in China
ReproNovo receives approval for RPN-001 Phase 1 trial in China from NMPA, a key step in global development for male infertility treatment. Company expanding clinical programs in the U.S. and China

China Male Infertility Clinical Trial ReproNovo RPN-001
BRIEF

published on 07/01/2025 at 07:05, 5 months 3 days ago

ReproNovo Initiates Phase 2 Trial for Male Infertility Drug in the U.S.

Male Infertility Phase 2 Trial ReproNovo RPN-001 Low Testosterone
BRIEF

published on 07/01/2025 at 07:05, 5 months 3 days ago

ReproNovo lance un essai de phase 2 pour un médicament contre l'infertilité masculine aux États-Unis

Essai De Phase 2 ReproNovo RPN-001 Infertilité Masculine Faible Taux De Testostérone
PRESS RELEASE

published on 07/01/2025 at 07:00, 5 months 3 days ago

REPRONOVO ANNOUNCES FIRST PARTICIPANT INCLUDED IN U.S. PHASE 2 TRIAL OF RPN-001 FOR MALE INFERTILITY
ReproNovo announces first participant in U.S. Phase 2 trial of RPN-001 for male infertility, aiming to develop oral therapy for low testosterone men with impaired semen quality

Male Infertility Phase 2 Trial ReproNovo RPN-001 Aromatase Inhibitor
BRIEF

published on 05/21/2025 at 07:05, 6 months 14 days ago

ReproNovo Secures $65 Million for Phase 2 Trials in Reproductive Health

Innovation Clinical Trials Series A Financing Reproductive Health ReproNovo
BRIEF

published on 05/21/2025 at 07:05, 6 months 14 days ago

ReproNovo obtient 65 millions de dollars pour des essais de phase 2 en santé reproductive

Innovation Essais Cliniques Financement De Série A Santé Reproductive ReproNovo
PRESS RELEASE

published on 05/21/2025 at 07:00, 6 months 14 days ago

REPRONOVO RAISES $65 MILLION SERIES A FINANCING TO ADVANCE PHASE 2 CLINICAL TRIALS OF NOVEL THERAPIES IN REPRODUCTIVE MEDICINE AND WOMEN’S HEALTH
ReproNovo raises $65 million in Series A financing to advance Phase 2 clinical trials of novel therapies in reproductive medicine and women’s health

Series A Financing Phase 2 Trials Women's Health ReproNovo Reproductive Medicine

Accesswire

Published on 12/05/2025 at 02:35, 4 hours 6 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 4 hours 11 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 5 hours 41 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 7 hours 36 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 7 hours 41 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 03:30, 3 hours 10 minutes ago

CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 6 hours 50 minutes ago

EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 10 hours 15 minutes ago

Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 10 hours 25 minutes ago

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 11 hours 30 minutes ago

SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance

Les Echos

Published on 12/04/2025 at 18:14, 12 hours 26 minutes ago

Résiliation d'une convention conclue entre actionnaires
Published on 12/04/2025 at 18:00, 12 hours 41 minutes ago

Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025
Published on 12/04/2025 at 18:00, 12 hours 41 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 12 hours 56 minutes ago

Informations relatives au nombre total de droits de vote et d’actions
Published on 12/04/2025 at 17:45, 12 hours 56 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL

View all LES ECHOS COMFI WIRE